Breaking News

Financial Report: Johnson & Johnson

July 15, 2014

Revenues up 9% in the quarter driven by new products

Johnson & Johnson
2Q Revenues: $19.5 billion (+9%)

2Q Earnings: $4.3 billion (+13%)

YTD Revenues: $37.6 billion (+6%)

YTD Earnings: $9.1 billion (+24%)

Comments: Pharmaceutical sales were $8.5 billion, up 21%, with domestic sales up 37% and international sales up 7%. Growth was primarily driven by new products including OLYSIO/SOVRIAD (simeprevir), for chronic hepatitis C; XARELTO (rivaroxaban), an oral anticoagulant; ZYTIGA for the treatment of metastatic, castration-resistant prostate cancer; INVOKANA for type 2 diabetes; and IMBRUVICA for the treatment of mantle cell lymphoma and chronic lymphocytic leukemia. Sales were negatively impacted by loss of exclusivity for ACIPHEX for gastrointestinal disorders, and CONCERTA, an ADHD treatment.
blog comments powered by Disqus
  • Staying Ahead in the Small Molecule Space

    Staying Ahead in the Small Molecule Space

    Dr. Matthew Moorcroft, VP Global Marketing, Cambrex||September 8, 2016
    Understand what is happening in the market and react accordingly

  • FDA & Drug Development

    FDA & Drug Development

    Rachelle Du2019Souza, Regulatory Heights Inc.||September 8, 2016
    You must perform the necessary due diligence to stay on top of regulatory developments

  • Patent Law  and Contract Manufacturing

    Patent Law and Contract Manufacturing

    Beverly W. Lubit, Member of the Firm, Chiesa Shahinian & Giantomasi||September 8, 2016
    Analyzing the impact of The Medicines Co. vs. Hospira Inc. decision